A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Divarasib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms Krascendo 170
Sponsors Roche

Most Recent Events

28 Jan 2025 Planned End Date changed from 10 May 2027 to 20 May 2027.
31 Dec 2024 Planned number of patients changed from 96 to 240.
28 Nov 2024 Planned End Date changed from 20 May 2027 to 10 May 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight